LAP+CD4+ T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5224-5233

  Mahalingam, Jayashri ^a,b   Lin, Yung Chang ^a,b   Chiang, Jy Ming ^a,b   Su, Po Jung ^a   Fang, Jian He ^a,b   Chu, Yu Yi ^a   Huang, Ching Tai ^a,b   Chiu, Cheng Tang ^a,b   Lin, Chun Yen ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER TISSUE; CELL FUNCTION; CELL LEVEL; CELL METABOLISM; CELL POPULATION; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LAP+ CD4+ T LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; PROTEIN PRECURSORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84866916324     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0211     Document Type: Article

References (45)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60. (Pubitemid 38680426)
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce- Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313: 1960-4. (Pubitemid 44498003)
3. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71.
4. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, Marrogi OL, et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997;74:492-501. (Pubitemid 27486505)
5. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non- small cell lung cancer. Clin Cancer Res 2008;14:5220-7.
6. Gandhi R, Anderson DE, Weiner HL. Cutting edge: immature human dendritic cells express latency-associated peptide and inhibit T cell activation in a TGF-beta-dependent manner. J Immunol 2007;178: 4017-21. (Pubitemid 46492348)
7. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006;55:237-45. (Pubitemid 41683212)
8. + T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2012;61:1163-71.
9. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008;8:887-99.
10. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011;71:2411-6.
11. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006;116:2132-41. (Pubitemid 44162322)
12. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, et al. NK cells and cancer. J Immunol 2007;178:4011- 6.
13. Maher J, Davies ET. Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br J Cancer 2004;91:817-21. (Pubitemid 39273768)
14. Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 2006;25:307-13. (Pubitemid 44922351)
15. Maeda H, Shiraishi A. TGF-beta contributes to the shift toward Th2- type responses through direct and IL-10-mediated pathways in tumorbearing mice. J Immunol 1996;156:73-8.
16. +CD45RBhigh-induced colitis by a TGF-beta- dependent mechanism. J Immunol 2003;170:2516-22. (Pubitemid 36245641)
17. Gandhi R, Farez MF, Wang Y, Kozoriz D, Quintana FJ, Weiner HL. Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset. J Immunol 2010;184:4620-4.
18. - regulatory T cells suppress allergic inflammation. J Immunol 2011;187:6499-507.
19. Lin YC, Chang LY, Huang CT, Peng HM, Dutta A, Chen TC, et al. Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. J Immunol 2009;182:6095-104.
20. Monteyne P, Guillaume B, Sindic CJ. B7-1 (CD80), B7-2 (CD86), interleukin-12 and transforming growth factor-beta mRNA expression in CSF and peripheral blood mononuclear cells from multiple sclerosis patients. J Neuroimmunol 1998;91:198-203. (Pubitemid 28545260)
21. Yin JL, Shackel NA, Zekry A, McGuinness PH, Richards C, Putten KV, et al. Real-time reverse transcriptase-polymerase chain reaction (RTPCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. Immunol Cell Biol 2001;79:213- 21.
22. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65-70. (Pubitemid 36020767)
23. Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, et al. LAG-3 expression defines a subset of CD4 (+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 2010;184:6545-51.
24. Xu L, kitani A, Strober W. Molecular mechanisms regulating TGF- [beta]-induced Foxp3 expression. Mucosal Immunol 2010;3:230-8.
25. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol 2010;28:4045-51.
26. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009;69:8412-9.
27. Miyazono K, Ichijo H, Heldin CH. Transforming growth factor-beta: latent forms, binding proteins and receptors. Growth Factors 1993;8: 11-22. (Pubitemid 23093207)
28. Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med 1995;1:932-7.
29. + regulatory T cell activity in both humans and mice. J Immunol 2004;172:834- 42.
30. + regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 2008;205:1975-81.
31. Byrne WL, Mills KHG, Lederer JA, O'Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res 2011;71:6915-20.
32. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005;202:1075-85. (Pubitemid 41464501)
33. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775-87. (Pubitemid 351707693)
34. + T cell function but not expansion. Nat Immunol 2002;3:1208- 13.
35. Feng G, Wood KJ, Bushell A. Regulatory T cell enrichment by IFNgamma conditioning. Methods Mol Biol 2011;677:281-301.
36. Feng T, Cao AT, Weaver CT, Elson CO, Cong Y. Interleukin-12 converts Foxp3+ regulatory T cells to interferon-gamma-producing Foxp3+ T cells that inhibit colitis. Gastroenterology 2011;140:2031-43.
37. Wood KJ, Feng G, Wei B, Sawitzki B, Bushell AR. Interferon gamma: friend or foe? Transplantation 2007;84 Suppl 1:S4 -5.
38. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009;114: 357- 9.
39. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15: 1016 - 22.
40. Middleton GW, Annels NE, Pandha HS. Are we ready to start studies of Th17 cell manipulation as a therapy for cancer? Cancer Immunol Immunother 2012;61:1- 7.
41. Allan SE, Chrome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al. Activation induced Foxp3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol.2007; 19:345-54. (Pubitemid 46523383)
42. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63. (Pubitemid 38680440)
43. Pepper M, Jenkins MK. Origins of CD4 (+) effector and central memory T cells. Nat Immunol 2011;12:467-71.
44. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718-27. (Pubitemid 36315986)
45. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27. (Pubitemid 46631379)